

Contents

Contributors	v
1. Introduction. Nanocarriers for Drug Delivery: Needs and Requirements	1
<i>Vladimir Torchilin</i>	
References	6
2. Nanoparticle Flow: Implications for Drug Delivery	9
<i>Alexander T. Florence</i>	
1 Introduction	9
2 Background	11
3 Studies on Nanoparticle Flow	13
4 Convection and Diffusion	13
5 Bifurcations	15
6 Interaction with Blood Constituents and Endogenous Molecules . .	16
7 Nanoparticles with Surface Ligands	18
8 Deposition on Surfaces and Attachment to Receptors in Flow Conditions	18
9 Does Shape Matter?	20
10 Speculations on Flow and the EPR Effect	21
11 Intra-tumoral Injection	22
12 Conclusions	23
References	24
3. Polymeric Nanoparticles as Drug Carriers and Controlled Release Implant Devices	29
<i>SM Moghimi, E Vega, ML Garcia, OAR Al-Hanbali and KJ Rutt</i>	
1 Introduction	29

2	Nanoparticle Engineering	30
2.1	Drug release mechanisms	32
3	Site-specific Targeting with Nanoparticles: Importance of Size and Surface Properties	33
4	Conclusions	37
	References	38
4.	Genetic Vaccines: A Role for Liposomes	43
	<i>Gregory Gregoriadis, Andrew Bacon, Brenda McCormack and Peter Laing</i>	
1	Introduction	43
2	The DNA Vaccine	44
3	DNA Vaccination via Liposomes	45
3.1	Procedure for the entrapment of plasmid DNA into liposomes	46
3.2	DNA immunization studies	47
3.3	Induction of a cytotoxic T lymphocyte (CTL) response by liposome-entrapped plasmid DNA	50
4	The Co-delivery Concept	51
	References	53
5.	Polymer Micelles as Drug Carriers	57
	<i>Elena V. Batrakova, Tatiana K. Bronich, Joseph A. Vetro and Alexander V. Kabanov</i>	
1	Introduction	57
2	Polymer Micelle Structures	58
2.1	Self-assembled micelles	58
2.2	Unimolecular micelles	61
2.3	Cross-linked micelles	62
3	Drug Loading and Release	63
3.1	Chemical conjugation	63
3.2	Physical entrapment	64
3.3	Polyionic complexation	66
4	Pharmacokinetics and Biodistribution	68
5	Drug Delivery Applications	72
5.1	Chemotherapy of cancer	72
5.2	Drug delivery to the brain	76
5.3	Formulations of antifungal agents	77
5.4	Delivery of imaging agents	77
5.5	Delivery of polynucleotides	78

6 Clinical Trials 79
 7 Conclusions 79
 References 80

6. Vesicles Prepared from Synthetic Amphiphiles — Polymeric Vesicles and Niosomes 95

Ijeoma Florence Uchegbu and Andreas G. Schatzlein

1 Introduction 95
 2 Polymeric Vesicles 96
 2.1 Polymer self assembly 97
 2.2 Polymers bearing hydrophobic pendant groups 98
 2.3 Block copolymers 101
 2.4 Preparing vesicles from self-assembling polymers 102
 2.5 Self assembling polymerizable monomers 103
 3 Polymeric Vesicle Drug Delivery Applications 104
 3.1 Drug targeting 104
 3.2 Gene delivery 105
 3.3 Responsive release 106
 3.3.1 pH 106
 3.3.2 Enzymatic 106
 3.3.3 Magnetic 107
 3.3.4 Oxygen 108
 4 Non-ionic Surfactant Vesicles (Niosomes) 108
 4.1 Self assembly 108
 4.2 Polyhedral vesicles and giant vesicles (Discomes) 111
 4.3 Vesicle preparation 113
 5 Niosome Delivery Applications 113
 5.1 Drug targeting 113
 5.1.1 Anti cancer drugs 113
 5.1.2 Anti infectives 115
 5.1.3 Delivery to the brain 115
 5.2 Topical use of niosomes 116
 5.2.1 Transdermal 116
 5.2.2 Ocular 116
 5.3 Niosomal vaccines 116
 5.4 Niosomes as imaging agents 117
 6 Conclusions 117
 References 117

7. Recent Advances in Microemulsions as Drug Delivery Vehicles 125

M Jayne Lawrence and Warankanga Warisnoicharoen

1	Definition	125
1.1	Microemulsion versus an emulsion	125
1.2	Microemulsion versus a nanoemulsion	126
1.3	Microemulsions	128
1.4	Microemulsions, swollen micelles, micelles	129
1.5	Microemulsions and cosolvent systems	130
2	Microemulsions as Drug Delivery Systems	130
2.1	Self-emulsifying drug delivery systems (SEDDS)	131
2.2	Related systems	133
2.2.1	Microemulsion gels	133
2.2.2	Double or multiple microemulsions	134
2.3	Processed microemulsion formulations	134
2.3.1	Solid state or dry emulsions	134
3	Formulation	135
3.1	Surfactants and cosurfactants	136
3.2	Oils	138
3.3	Characterization	139
4	Routes of Administration	139
4.1	Oral	139
4.1.1	Proteins and peptides	140
4.1.2	Other hydrophilic molecules	141
4.1.3	Hydrophobic drugs	142
4.2	Buccal	144
4.3	Parenteral	144
4.3.1	Long circulating microemulsions	147
4.3.2	Targeted delivery	148
4.4	Topical delivery	148
4.4.1	Dermal and transdermal delivery	148
4.5	Ophthalmic	154
4.6	Vaginal	156
4.7	Nasal	157
4.8	Pulmonary	158
4.8.1	Antibacterials	159
5	Conclusion	160
	References	160

8. Lipoproteins as Pharmaceutical Carriers 173

Suwen Liu, Shining Wang and D. Robert Lu

1	Introduction	173
2	The Structure of Lipoproteins	174
3	Chylomicron as Pharmaceutical Carrier	175
4	VLDL as Pharmaceutical Carrier	176
5	LDL as Pharmaceutical Carrier	177
5.1	LDL as anticancer drug carriers	178
5.2	LDL as carriers for other types of bioactive compounds	179
5.3	LDL for gene delivery	179
6	HDL as Pharmaceutical Carriers	179
7	Cholesterol-rich Emulsions (LDE) as Pharmaceutical Carriers	180
8	Concluding Remark	181
	References	182

9. Solid Lipid Nanoparticles as Drug Carriers 187

Karsten Mäder

1	Introduction: History and Concept of SLN	187
2	Solid Lipid Nanoparticles (SLN) Ingredients and Production	188
2.1	General ingredients	188
2.2	SLN preparation	189
2.2.1	High shear homogenization and ultrasound	189
2.3	High pressure homogenization (HPH)	189
2.4	Hot homogenization	190
2.5	Cold homogenization	190
2.5.1	SLN prepared by solvent emulsification / evaporation	191
2.5.2	SLN preparations by solvent injection	191
2.5.3	SLN preparations by dilution of microemulsions or liquid crystalline phases	192
2.6	Further processing	193
2.6.1	Sterilization	193
2.6.2	Drying by lyophilization, nitrogen purging and spray drying	194
3	SLN Structure and Characterization	196
4	The "Frozen Emulsion Model" and Alternative SLN Models	200
5	Nanostructured Lipid Carriers (NLC)	201
6	Drug Localization and Release	202

7	Administration Routes and <i>In Vivo</i> Data	203
8	Summary and Outlook	205
	References	205
10.	Lipidic Core Nanocapsules as New Drug Delivery Systems	213
	<i>Patrick Saulnier and Jean-Pierre Benoit</i>	
1	Introduction	213
2	Lipidic Nanocapsule Formulation and Structure	215
2.1	Process	215
2.2	Influence of the medium composition	216
2.3	Structure and purification of the LNC by dialysis	217
2.4	Imagery techniques	218
3	Electrical and Biological Properties	219
3.1	Electro kinetic comportment	219
3.2	Evaluation of complement system activation	220
4	Pharmacokinetic Studies and Biodistribution	220
5	Drug Encapsulation and Release	222
5.1	Ibuprofene	222
5.2	Amiodarone	223
6	Conclusions	223
	References	224
11.	Lipid-Coated Submicron-Sized Particles as Drug Carriers	225
	<i>Evan C. Unger, Reena Zutshi, Terry O. Matsunaga and Rajan Ramaswami</i>	
1	Technology	225
2	Ultrasound Contrast Agents	228
3	Sonothrombolysis	232
4	Clinical Studies	237
5	Blood Brain Barrier	239
6	Drug Delivery	242
6.1	Targeted bubbles	242
6.2	Targeted submicron-sized droplets	244
7	Gene Delivery	245
8	Oxygen Delivery	247
9	Pulmonary Delivery	248
10	Conclusion	249
	References	250

12. Nanocapsules: Preparation, Characterization and Therapeutic Applications **255**

Ruxandra Gref and Patrick Couvreur

- 1 Introduction 255
- 2 Preparation 257
 - 2.1 Nanocapsules obtained by interfacial polymerization 257
 - 2.1.1 Oil-containing nanocapsules 257
 - 2.1.2 Nanocapsules containing an aqueous core 259
 - 2.2 Nanocapsules obtained from preformed polymers 261
- 3 Characterization 263
- 4 Drug Release 265
- 5 Applications 266
 - 5.1 Oral route 266
 - 5.2 Parenteral route 267
 - 5.3 Ocular delivery 269
- 6 Conclusion 270
- References 271

13. Dendrimers as Nanoparticulate Drug Carriers **277**

Sönke Svenson and Donald A. Tomalia

- 1 Introduction 277
- 2 Nanoscale Containers — Micelles, Dendritic Boxes, Dendrophanes, and Dendroclefts 279
 - 2.1 Dendritic micelles 279
 - 2.2 Dendritic box (Nano container) 280
 - 2.3 Dendrophanes and dendroclefts 282
- 3 Dendrimers in Drug Delivery 282
 - 3.1 Cisplatin 283
 - 3.2 Silver salts 285
 - 3.3 Adriamycin, methotrexate, and 5-fluorouracil 285
 - 3.4 Etoposide, mefenamic acid, diclofenac, and venlafaxine 286
 - 3.5 Ibuprofen, indomethacin, nifedipine, naproxen, paclitaxel, and methylprednisolone 287
 - 3.6 Doxorubicin and camptothecin — self-immolative dendritic prodrugs 289
 - 3.7 Photodynamic therapy (PDT) and boron neutron capture therapy (BNCT) 291

4	Nano-Scaffolds for Targeting Ligands	292
4.1	Folic acid	292
4.2	Carbohydrates	293
4.3	Antibodies and biotin-avidin binding	294
4.4	Penicillins	295
5	Dendrimers as Nano-Drugs	295
6	Routes of Application	296
7	Biocompatibility of Dendrimers	297
8	Conclusions	299
	References	299
14.	Drug Nanocrystals/Nanosuspensions for the Delivery of Poorly Soluble Drugs	307
	<i>Rainer H. Müller and Jens-Uwe A. H. Junghanns</i>	
1	Introduction	307
2	Definitions	308
3	Physicochemical Properties of Drug Nanocrystals	309
3.1	Change of dissolution velocity	309
3.2	Saturation solubility	309
3.3	Does size really matter?	311
3.4	Effect of amorphous particle state	312
4	Production Methods	313
4.1	Precipitation methods	313
4.1.1	Hydrosols	313
4.1.2	Amorphous drug nanoparticles (NanoMorph®)	313
4.2	Homogenization methods	314
4.2.1	Microfluidizer technology	314
4.2.2	Piston-gap homogenization in water (Dissocubes®)	314
4.2.3	Nanopure technology	315
4.3	Combination Technologies	315
4.3.1	Microprecipitation™ and High Shear Forces (NANOEDGE™)	315
4.3.2	Nanopure® XP technology	316
5	Application Routes and Final Formulations	317
5.1	Oral administration	317
5.2	Parenteral administration	319
5.3	Miscellaneous administration routes	321
6	Nanosuspensions as Intermediate Products	322

7 Perspectives 324
 References 324

15. Cells and Cell Ghosts as Drug Carriers 329

José M. Lanao and M. Luisa Sayalero

1 Introduction 329
 2 Bacterial Ghosts 329
 2.1 Application of bacterial ghosts as a delivery system 331
 3 Erythrocyte Ghosts 333
 3.1 Applications of erythrocyte ghosts as a delivery system 335
 4 Stem Cells 338
 5 Polymorphonuclear Leucocytes 340
 6 Apoptotic Cells 340
 7 Tumor Cells 340
 8 Dendritic Cells 341
 9 Conclusions 341
 References 342

16. Cochleates as Nanoparticulate Drug Carriers 349

Leila Zarif

1 Introduction 349
 2 Cochleates Nanoparticles in Oral Delivery 350
 2.1 Cochleate structure 350
 2.2 Cochleate preparation 350
 2.2.1 Which phospholipid and which cation to use? 350
 2.2.2 Which molecules can be entrapped in cochleates nanoparticles 352
 2.2.3 Multiple ways of preparing cochleates 353
 2.3 Cochleates as oral delivery system for antifungal agent, amphotericin B 355
 2.3.1 In candidiasis animal model 355
 2.3.2 In aspergillosis animal model 355
 2.3.3 In cryptococcal meningitis animal model 357
 2.3.4 Toxicity of amphotericin B cochleates 357
 2.3.5 Pharmacokinetics of amphotericin B cochleates 357
 2.4 Other potential applications for cochleates 359
 2.4.1 Cochleate for the delivery of antibiotics 359
 2.4.2 Delivery of clofazimine 360

2.4.3	Delivery of tobramycin	360
2.4.4	Cochleate for the delivery of anti-inflammatory drugs	361
2.5	Other uses of cochleates	361
3	Conclusion	361
	References	362

17. Aerosols as Drug Carriers 367

N. Renée Labiris, Andrew P. Bosco and Myrna B. Dolovich

1	Introduction	367
2	Pulmonary Drug Delivery Devices	369
2.1	Nebulizers	369
2.2	Metered-dose inhalers	371
2.3	Dry powder inhalers	373
3	Aerosol Particle Size	373
4	Targeting Drug Delivery in the Lung	376
5	Clearance of Particles from the Lung	378
5.1	Airway geometry and humidity	378
5.2	Lung clearance mechanisms	379
6	Nanoparticle Formulations for Inhalation	381
6.1	Diagnostic imaging	382
6.2	Vaccine delivery	383
6.3	Anti Tuberculosis therapy	385
6.4	Gene therapy	386
7	Conclusion	388
	References	388

18. Magnetic Nanoparticles as Drug Carriers 397

Urs O. Häfeli and Mathieu Chastellain

1	Introduction	397
2	Definitions	398
2.1	Properties of magnetic materials	398
2.2	Nanoparticles	400
3	Magnetic Nanoparticles	401
3.1	Iron oxide based magnetic nanoparticles	401
3.2	Cobalt based magnetic nanoparticles	402
3.3	Iron based magnetic particles	402
3.4	Encapsulated magnetic nanoparticles	403
3.5	Biocompatibility issues of magnetic nanoparticles	403

4	Application of Magnetic Nanoparticles as Drug Carriers	404
4.1	Magnetic hyperthermia	405
4.2	Magnetic chemotherapy	406
4.3	Other magnetic treatment approaches	408
4.4	Magnetic gene transfer	409
5	Conclusions	410
	References	411
19.	DQAsomes as Mitochondria-Specific Drug and DNA Carriers	419
	<i>Volkmar Weissig</i>	
1	Introduction	419
2	The Self Assembly Behavior of Bis Quinolinium Derivatives	420
2.1	Monte Carlo computer simulations	420
2.2	Physico-chemical characterization	421
2.3	Structure activity relationship studies	422
3	DQAsomes as Mitochondrial Transfection Vector	424
4	DQAsomes as Carriers of Pro-apoptotic Drugs	429
5	Summary	432
	References	432
20.	Liposomal Drug Carriers in Cancer Therapy	437
	<i>Alberto A. Gabizon</i>	
1	Introduction	437
2	The Challenge of Cancer Therapy	439
3	The Rationale for the Use of Liposomal Drug Carriers in Cancer	442
4	Liposome Formulation and Pharmacokinetics — Stealth Liposomes	445
5	Preclinical Observations with Liposomal Drug Carriers in Tumor Models	448
6	Liposomal Anthracyclines in the Clinic	449
6.1	Doxil	450
6.2	Myocet	454
6.3	Daunoxome	454
7	Clinical Development of Other Liposome-entrapped Cytotoxic Agents	455
8	The Future of Liposomal Nanocarriers	456
	References	457

21. Nanoparticulate Drug Delivery to the Reticuloendothelial System and to Associated Disorders	463
<i>Mukul Kumar Basu and Sanchaita Lala</i>	
1 Introduction	463
2 Reticuloendothelial System and Associated Disorders	464
3 Uptake of Nanoparticles by the Reticuloendothelial System	464
3.1 Sites of uptake	464
3.2 Mechanism of uptake	465
3.3 Factors influencing uptake	468
3.4 Role of surface modifications on uptake	469
4 Active Targeting of Nanoparticles by Receptor Mediated Endocytosis	471
5 Application in Chemotherapy	473
6 Summary	475
References	477
22. Delivery of Nanoparticles to the Cardiovascular System	481
<i>Ban-An Khaw</i>	
1 Introduction	481
2 Targeting the Myocardium with Immunoliposomes	481
3 Other Nanoparticle-Targeting of the Cardiovascular System	484
4 Novel Application of Nano-Immunoliposomes	485
5 CSIL as Targeted Gene or Drug Delivery	492
6 Conclusion	495
References	496
23. Nanocarriers for the Vascular Delivery of Drugs to the Lungs	499
<i>Thomas Dziubla and Vladimir Muzykantov</i>	
1 Introduction	500
2 Biomedical Aspects of Drug Delivery to Pulmonary Vasculature	500
2.1 Routes for pulmonary drug delivery: Intratracheal vs vascular	501
2.2 Pulmonary vasculature as a target for drug delivery	501
3 Pulmonary Targeting of Nanocarriers	503
3.1 Effects of carrier size on circulation and tissue distribution	503

3.2	Passive targeting	505
3.2.1	Mechanical retention	505
3.2.2	Charge-mediated retention and non-viral gene delivery	506
3.2.3	Pulmonary enhanced permeation-retention (EPR) effect	507
3.3	Active targeting	507
4	Carrier Design	509
4.1	Biocompatibility	509
4.2	Material selection (by application)	510
4.2.1	Imaging	510
4.2.2	Gene delivery	510
4.2.3	Delivery of therapeutic enzymes	511
4.2.4	Small molecule drugs	512
4.3	Types of nanocarriers	512
4.4	Mechanisms of drug loading	512
4.5	Drug release mechanisms	515
4.6	Nanocarriers for active targeting	516
5	Conclusion: Safety Issues, Limitations and Perspectives	517
	References	518

24. Nanoparticulate Carriers for Drug Delivery to the Brain 527

Jörg Kreuter

1	Introduction	527
2	Nanoparticles	528
3	Biodistribution	530
3.1	Influence of surfactants on the biodistribution of nanoparticles	530
3.2	Influence of PEGylation on the biodistribution of nanoparticles	532
4	Pharmacology	534
5	Brain Tumors	536
6	Toxicology	538
7	Mechanism of the Delivery of Drug Across the Blood-Brain Barrier with Nanoparticles	539
8	Summary	541
9	Conclusions	542
	References	542

25. Nanoparticles for Targeting Lymphatics	549
<i>William Phillips</i>	
1 Introduction	549
1.1 The lymphatic vessels	550
1.2 Lymph nodes	551
2 Potential for Nanoparticles for Drug Delivery to Lymphatics	553
3 Importance of Lymph Nodes for Disease Spread and Potential Applications of Lymph Node Drug Delivery	554
3.1 Cancer	554
3.2 HIV	555
3.3 Filaria	555
3.4 Anthrax	556
3.5 Tuberculosis	556
3.6 Importance of lymph node antigen delivery for development of an immune response	557
4 Factors Influencing Nanoparticle Delivery to Lymph Nodes	559
4.1 Nanoparticle size	559
4.2 Nanoparticle surface	559
4.3 Effect of massage on lymphatic clearance of subcutaneously injected liposomes	560
4.4 Macrophage phagocytosis	561
4.5 Fate of nanoparticles in lymph nodes	561
5 Nanoparticle Diagnostic Imaging Agents for Determining Cancer Status of Lymph Nodes	561
5.1 Subcutaneous injection of iodinated nanoparticles for computed tomography imaging	561
5.2 Subcutaneous and intraorgan injection of magnetic resonance (MRI) contrast agents	563
5.3 Intravenous injection of magnetic nanoparticles for MRI imaging	563
5.4 Nanoparticle diagnostic agents for localizing the sentinel lymph node	565
5.5 Radiolabeled nanoparticles for sentinel lymph node identification	566
5.6 ^{99m} Tc-Colloidal nanoparticles for sentinel node identification .	566
5.7 Optical	568
5.8 Ultrasound nanobubbles	569
6 Recently Introduced Medical Imaging Devices for Monitoring Lymph Node Delivery and Therapeutic Response	569

7 Nanoparticle Lymph Node Drug Delivery 571
 7.1 Confusion in reporting lymph node delivery 571
 7.2 Calculation of lymph node retention efficiency 573
 8 Specific Types Nanoparticles for Lymph Node Targeting 573
 8.1 PLGA nanoparticles 573
 8.2 Micelles 574
 8.3 Liposomes 574
 9 Avidin Biotin-Liposome Lymph Node Targeting Method 577
 10 Massage and the Avidin-Biotin Liposome Targeting Method 578
 11 Nanoparticles for Lymph Node Anti-Infectious Agent Delivery 580
 12 Liposomes for Intraperitoneal Lymph Node Drug Delivery 581
 12.1 Intraperitoneal liposome encapsulated drugs 582
 12.2 Effect of liposome size on intraperitoneal clearance 583
 12.3 Avidin/Biotin-liposome system for intraperitoneal and lymph node drug delivery 584
 12.4 Mediastinal lymph node drug delivery with avidin-biotin system by intrapleural injection 585
 12.5 Avidin biotin for diaphragm and mediastinal lymph node targeting 586
 13 Nanoparticles for Cancer Therapy 587
 13.1 Intralymphatic drug delivery to lymph nodes 587
 13.2 Nanoparticles for treatment of metastatic lymph nodes of upper GI malignacies 589
 13.3 Lessons from endolymphatic radioisotope therapy 591
 14 Advantages of Nanoparticles for Lymphatic Radiotherapy 592
 15 Intraoperative Radiotherapy for Positive Tumor Margins and for Treatment of Lymph Nodes 593
 16 Potential of Using Radiolabeled Nanoparticles for Intratumoral Radionuclide Therapy 593
 17 Liposome Pharmacokinetics after Intratumoral Administration 595
 18 Rhenium-Labeled Liposomes for Tumor Therapy 595
 19 Nanoparticles for Immune Modulation 597
 20 Conclusions 598
 References 598

26. Polymeric Nanoparticles for Delivery in the Gastro-Intestinal Tract 609

Mayank D. Bhavsar, Dinesh B. Shenoy and Mansoor M. Amiji

1 Oral Drug Delivery 609

2	Anatomical and Physiological Considerations of Gastro-intestinal Tract (GIT) for Delivery	610
3	Introduction to Polymeric Nanoparticles as Carriers	614
4	Preparation of Polymeric Nanoparticles	615
5	Design Consideration for Nanoparticle-based Delivery Systems	619
5.1	Polymer characteristics	619
5.2	Drug characteristics	620
5.3	Application characteristics	621
6	Nanoparticles in Experimental and Clinical Medicine	621
6.1	Drug delivery in the oral cavity	621
6.2	Gastric mucosa as a target for oral nanoparticle-mediated therapy	625
6.3	Nanoparticles for delivery of drugs and vaccines in the small intestine	626
6.4	Nanoparticles for colon-specific delivery	632
7	Integrating Polymeric Nanoparticles and Dosage Forms	634
8	Toxicology and Regulatory Aspects	636
8.1	Safety	637
8.2	Quality of material/characterization	638
8.3	Environmental considerations	638
9	Conclusion and Outlook	639
	References	640

27. Nanoparticulate Carriers for Ocular Drug Delivery 649

Alejandro Sanchez and Maria J. Alonso

1	Biopharmaceutical Barriers in Ocular Drug Delivery. Classification of Nanoparticulate Carriers for Ocular Drug Delivery	650
2	Nanoparticulate Polymer Compositions as Topical Ocular Drug Delivery Systems	651
2.1	First generation: Polymer nanoparticles and nanocapsules for topical ocular drug delivery	652
2.1.1	Acrylic polymers-based nanoparticles	654
2.1.2	Polyester-based nanoparticles and nanocapsules	655
2.1.3	Polysaccharide-based nanoparticles	657
2.2	Second nanoparticles generation: The coating approach	659
2.2.1	Polyacrylic coating	659
2.2.2	Polysaccharide coating	660
2.2.3	Polyethyleneglycol (PEG) coating	662

2.3	Third nanoparticles generation: Towards functionalized nanocarriers	663
3	Nanoparticulate Polymer Compositions as Subconjunctival Drug Delivery Systems	665
4	Nanoparticulate Polymer Compositions as Intravitreal Drug Delivery Systems	665
5	Conclusions and Outlook	667
	References	668
28.	Nanoparticles and Microparticles as Vaccine Adjuvants	675
	<i>Janet R. Wendorf, Manmohan Singh and Derek T. O'Hagan</i>	
1	Introduction	675
2	Nanoparticle and Microparticle Preparation Methods	678
2.1	Nanoparticles and microparticles made from polyesters	678
2.2	Nanoparticles and microparticles made with chitosan	681
2.3	Other nanoparticles and microparticles	681
3	Adjuvant Effect of Nanoparticles and Microparticles	681
3.1	Nanoparticles and microparticles as mucosal adjuvants	682
3.2	Nanoparticles and microparticles as systemic adjuvants	686
4	Delivery of DNA Using Nanoparticles and Microparticles	688
5	Conclusions	690
	References	691
29.	Pharmaceutical Nanocarriers in Treatment and Imaging of Infection	697
	<i>Raymond M. Schiffelers, Gert Storm and Irma A. J. M. Bakker-Woudenberg</i>	
1	Introduction	697
2	Carriers that are Easily Recognized as Foreign Materials	698
3	Carriers that Avoid Recognition as Foreign Materials	701
4	Local Application of Carriers	705
5	Concluding Remarks	706
	References	707
Index		713